Vétoquinol is Eligible for New PEA-PME Funds

Regulatory News:

Vétoquinol (Paris:VETO) confirms that it qualifies for the PEA-PME investment product in accordance with Decree n°. 2014-283 on 4 March 2014 reflecting the application of Article 70 of 2014 finance law (n°. 2013-1278 dated 29 December 2013) which set the conditions of companies’ eligibility for the PEA-PME as follows:

• less than 5,000 employees,
• annual revenues of less than €1,500 million,
• or total balance sheet of less than €2,000 million,
• these criteria apply to the Vétoquinol Group taken as a whole.

Upcoming event: Publication of Q1 2014 sales - April 15, 2014 after market close

About Vétoquinol
Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.
An independent pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs over 1,850 people.
Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

VETOQUINOL – 34 rue du Chêne Sainte Anne - Magny-Vernois – 70204 Lure Cedex – France
www.vetoquinol.com